EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 November 2018
EMA/824408/2018
EMEA/H/C/002735

Public statement

Eperzan

Withdrawal of the marketing authorisation in the European Union

On 29 October 2018, the European Commission withdrew the marketing authorisation for Eperzan (albiglutide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, GlaxoSmithKline Trading Services Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Eperzan was granted marketing authorisation in the EU on 21 March 2014 for the treatment of type 2 diabetes mellitus.

The European Public Assessment Report (EPAR) for Eperzan will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact